Companies / Italy
Sales Stagnate For Recordati
February 2007 | Company Finance AlertItalian drugmaker Recordati has reported flat revenues for 2006, with turnover reaching EUR576.2mn (US$757.3mn) form a figure of EUR576.1mn (US$757.2mn) in 2005, primarily due to a 7.8% fall in domestic sales. However, the company managed to post a double-digit increase in earnings, with net income rising 14.7% to EUR74mn (US$97.2mn). Recordati claims that increased profitability has primarily been due to the success of its flagship hypertension treatment Zanidip (lercanidipin), and 'the careful management of the company's resources'.
To read the full article, please choose one of the following options:
Subcribers please log in




